drugset / Trial / NCT01527695

PET Study in Parkinson's Disease Patients

NCT01527695

Phase 2 Completed 24 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

This is a multi-centre study to be conducted in Sweden and Finland. Up to 24 male and/or female patients of non-childbearing potential aged 45 to 75 years (inclusive), with a clinical diagnosis Parkinson's Disease will be randomised in the study to allow for 20 patients to complete this study.The study will evaluate the effect of 8 weeks treatment with AZD3241 on microglia activation as measured via PET examinations.

Timeline

Start
2012-04
Primary completion
2012-12
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Verdiperstat Small molecule 600 mg Oral

Indications